研究成果: |
发表论文
(1)Zhao J, Zhao M, Yu C, Zhang X, Liu J, Cheng X, Lee RJ, Sun F, Teng L, Li Y. Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis. Int J Nanomedicine, Int J Nanomedicine. 2017;12:6735-6746.
(2)Zhao J, Wang L, Fan C, Yu K, Liu X, Zhao X, Wang D, Liu W, Su Z, Sun F*, Li Y*. Development of near zero-order release PLGA-based microspheres of a novel antipsychotic. Int J Pharm. 2017;516(1-2):32-38.
(3)Liu W, Teng L, Yu K, Sun X, Fan C, Long C, Liu N, Li S, Wu B, Xu Q, Sun F*, Li Y*. Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. Eur J Pharm Sci. 2017;96:530-541.
(4)Yu K, Zhou Y, Li Y, Sun X, Sun F, Wang X, Mu H, Li J, Liu X, Teng L, Li Y. Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Biomater Sci. 2016;4(8): 1219-32.
(5)Fu J, Sun F, Liu W, Liu Y, Gedam M, Hu Q, Fridley C, Quigley HA, Hanes J, Pitha I. Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits. Mol Pharm. 2016;13(9):2987-95.
(6)Yu K, Zhao J, Yu C, Sun F, Liu Y, Zhang Y, Lee RJ, Teng L, Li Y. Role of Four Different Kinds of Polyethylenimines (PEIs) in Preparation of Polymeric Lipid Nanoparticles and Their Anticancer Activity Study. J Cancer. 2016;7(7): 872-82.
(7)Wang C, Yu C, Liu J, Teng L, Sun F*, Li Y*. Preparation and in vivo evaluation of PCADK/PLGA microspheres for improving stability and efficacy of rhGH. Int J Pharm. 2015;495(2):924-31.
(8)Wang C, Yu C, Liu J, Sun F, Teng L, Li Y. Stabilization of Human Immunoglobulin G Encapsulated within Biodegradable Poly (Cyclohexane-1, 4-diyl Acetone Dimethylene Ketal) (PCADK)/ Poly (Lactic-co-Glycolic Acid) (PLGA) Blend Microspheres. Protein Pept Lett. 2015;22(11):963-71.
(9)Dai W, Wang C, Yu C, Yao J, Sun F, Teng L, Li Y. Preparation of a mixed-matrix hydrogel of vorinostat for topical administration on the rats as experimental model. Eur J Pharm Sci. 2015;78:255-63
(10)Wang C, Yu C, Yu K, Teng L, Liu J, Wang X, Sun F*, Li Y*. Improving Protein Stability and Controlling Protein Release by Adding Poly (Cyclohexane-1, 4-Diyl Acetone Dimethylene Ketal) to PLGA Microspheres. Curr Drug Deliv. 2015;12(6):726-35.
(11)Li X, Wang C, Liang R, Sun F, Shi Y, Wang A, Liu W, Sun K, Li Y. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm Res. 2015;32(3):1017-27.
(12)Liu X, Fu L, Dai W, Liu W, Zhao J, Wu Y, Teng L, Sun F*, Li Y*. Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. Int J Pharm. 2014;471(1-2):322-31.
(13)Wang D, Zhao J, Liu X, Sun F, Zhou Y, Teng L, Li Y. Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation. Eur J Pharm Sci. 2014;60:40-8
(14)Zhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, Sun F, Liu W, Wang D, Jin J, Li Y. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats. PLoS One. 2014;9(3):e91775.
(15)Li X, Zhang R, Liang R, Liu W, Wang C, Su Z, Sun F*, Li Y*. Preparation and characterization of sustained-release rotigotine film-forming gel. Int J Pharm. 2014;460(1-2):273-9.
(16)Sun F, Sui C, Zhou Y, Liu X, Shi Y, Wu Y, Li Y. Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. Int J Pharm. 2013; 454(1):532-8.
(17)Teng L, Jiang C, Sun F, Li C, Teng L, Meng Q, Lee RJ, Li Y. Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder. J Microencapsul. 2013; 30(2):116-23.
(18)Wang L, Wang A, Zhao X, Liu X, Wang D, Sun F*, Li Y*. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism. Int J Pharm. 2012; 427(2):284-92.
(19)Sun F, Su Z, Sui C, Zhang C, Yuan L, Meng Q, Teng L, Li Y. Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats. Basic Clin Pharmacol Toxicol. 2010; 107(2):656-62.
(20)Sun F, Sui C, Teng L, Liu X, Teng L, Meng Q, Li Y. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. Int J Pharm. 2010; 397(1-2):44-9.
(21)Su Z, Sun F, Shi Y, Jiang C, Meng Q, Teng L, Li Y. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Chem Pharm Bull (Tokyo). 2009; 57(11):1251-6.
(22)黄晚,王晨晖,杞少鋆,姚举,孙凤英*. 药用乳糖性质对低剂量片剂含量均匀度的影响. 东北师大学报(自然科学版). 2013; 45(3):130-7.
(23)刘文华,潘振祥,李又欣,孙凤英*. 托特罗定PLGA微球的制备及其体外释药的研究. 中国新药杂志. 2012; (23):2821-5.
(24)Pharmacokinetic evaluation of tolterodine hydrogels in rabbits. 2013 CRS Annual Meeting.
(25)Effects of paliperidone prodrugs on MK-801-induced locomotion and stereotypy. 2011 CRS Annual Meeting.
(26)孟庆繁, 孙凤英, 田晓乐, 滕利荣等. 鼠妇水提物的镇痛作用. 99905银河官方网学报(医学版). 2005; 31(4):501-3.
(27)孙凤英, 睢诚, 滕利荣, 王贞佐等. 托特罗定微球的制备和体外释放的研究. 吉林省第六届生命科学大型学术报告会. 2008; 64-5.
(28)孙凤英, 刘艳, 李微, 滕利荣等. 鼠妇中镇痛物质的提取及其镇痛研究. 第三届全国制药工程科技与教育研讨会. 2004: 218-21.
专利成果
(1)刘文华,刘佳欣,郑舒婷,孙凤英,滕利荣,李又欣. 一种5-羟甲基托特罗定脂质体凝胶制剂及其制备方法. ZL201610464478.9. 2017.
(2)李又欣,赵金龙,孙凤英,刘喜明,王晨晖,余昌会. 一种含小分子添加剂的托特罗定缓释微球制剂及制备方法. CN 10612201. 2015.
(3)滕乐生,王晨晖,余昌会,赵金龙,刘佳欣,孙凤英,李又欣. 一种异丁利酮片剂及制备方法. CN 10613457. 2015.
(4)滕利荣, 孟庆繁, 田晓乐, 孙凤英, 李微. 鼠妇镇痛肽及其制备方法和应用. CN 100391533. 2008.
奖励信息
(1)孙凤英(2/8),前体药物设计及新型缓控释传递系统的研究,吉林省科学技术协会,自然科学,省部二等奖,2014(李又欣,孙凤英,史亚楠,王爱萍,梁荣财,李想,张人昱,黄晚)
科研项目
(1)注射用丙氨瑞林微球的制备工艺开发研究,长春健欣生物医药科技开发有限公司,2016/06-2019/6,10万元,在研,主持。
(2)聚乙二醇重组人生长激素注射液二次开发,吉林省省校共建计划专项,2017/09-2020/09,200万元,在研,主持。
(3)具有双重精准识别功能的单抗靶向型脱氧核酶传输体系的构建与评价,国家自然科学基金面上项目,2014/01-2017/12,65万元,在研,参加。
(4)作为毒蕈碱受体拮抗剂的3,3-二苯基丙胺衍生物注射用缓释微球制剂研究,吉林省医药专项重大项目,2012/07-2015/06,50万元,已结题,主持。
(5)PLGA/聚缩酮蛋白微球的制备及蛋白-微球材料的生物相容性研究,吉林省科技厅青年基金,2013/01-2015/12,3万元,已结题,主持。
(6)聚缩酮材料的生物相容性研究,山东绿叶制药有限公司,2012/09-2014/08,20万元,已结题,主持。
(7)异丁立酮片剂和长效微球的研究,长春健欣生物医药科技开发有限公司,2011/09-2012/09,124.2万元,已结题,主持。
(8)治疗精神分裂症候选药物帕潘立酮前体化合物的研究,十二五 国家科技重大专项,2009/01-2010/12,145万元,已结题,参加。
(9)治疗精神分裂疾病药物-帕潘利酮前体化合物缓释片研究,吉林省科学技术厅自然科学基金,2009/06-2010/12,12万元,已结题,参加。
(10)利培酮长效微球冻干粉针制剂,珐玛诺医药研发(北京)有限公司,
2008/01-2013/12,273.6万元,已结题,参加。 |